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Abstract
Introduction: In this study, we investigated possible aberrations of monocytes from patients with primary
Sjögren’s syndrome (pSS). We focused on B-cell-activating factor of the TNF family (BAFF) and IL-6 because they
are both produced by monocytes and are known to be involved in the pathogenesis of pSS.
Methods: Peripheral monocytes were prepared from both pSS patients and normal individuals. The cells were
stimulated in vitro with IFN-g, and the amounts of IL-6 and soluble BAFF (sBAFF) produced by the cells were
quantitated. The effect of sBAFF itself on the production of IL-6 was also studied. To investigate the response of
pSS monocytes to these stimuli, the expression levels of the genes encoding BAFF receptors and IL-6-regulating
transcription factors were quantitated.
Results: Peripheral pSS monocytes produced significantly higher amounts of sBAFF and IL-6 than normal
monocytes did, even in the absence of stimulation. The production of these cytokines was significantly increased
upon stimulation with IFN-g. The elevated production of IL-6 was significantly suppressed by an anti-BAFF
antibody. In addition, stimulation of pSS monocytes with sBAFF induced a significant increase in IL-6 production.
Moreover, the expression levels of a BAFF receptor and transcription factors regulating IL-6 were significantly
elevated in pSS monocytes compared to normal monocytes.
Conclusions: The results of the present study suggest that the mechanisms underlying the production of sBAFF
and IL-6 are impaired in pSS monocytes. Our research implies that this impairment is due to abnormally
overexpressed IL-6-regulating transcription factors and a BAFF receptor. These abnormalities may cause the
development of pSS.
Introduction
Sjögren’ss y n d r o m e( S S )i sa na u t o i m m u n ed i s e a s e
which primarily affects the salivary and lachrymal
glands. Major clinical manifestations of primary SS
(pSS) are xerostomia and keratoconjunctive sicca, which
are consequences of lesions of the salivary glands and
lachrymal glands, respectively. Accumulating evidence
suggests that lymphocytic infiltrate of exocrine glands
p l a y sak e yr o l ei nl e s i o nf o r m a t i o na n dt h es u b s e q u e n t
dysfunction of the glands [1].
B-cell-activating factor of the TNF family (BAFF)
(tumor necrosis factor ligand superfamily, member 13b)
is a cytokine which is primarily produced by monocytes
and dendritic cells [2-4] in addition to T cells [5,6]. It
plays a crucial role in the proliferation, differentiation
and survival of B cells [2,4,5,7]. BAFF is a type II mem-
brane-bound protein of 285 amino acid residues. A C-
terminal fragment of 152 amino acid residues is released
from cells as soluble BAFF (sBAFF) [5]. sBAFF binds to
its receptors (that is, transmembrane activator and cal-
cium modulator and cyclophilin ligand interactor
(TACI), B cell maturation antigen (BCMA) and B cell
activating factor receptor (BAFF-R) [8-14]), possibly as a
trimer [8,11,13], and elicits signal transduction through
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transgenic mice that overexpress BAFF in lymphoid
cells develop hyperplasia of mature B cells [8,17,18] or
pSS-like pathology [19]. BAFF is also elevated in the
serum of pSS patients [20,21] and strongly expressed in
the lymphocytes infiltrating the salivary glands [22,23].
Moreover, elevated production of BAFF has been linked
to the development of another autoimmune disease, sys-
temic lupus erythematosus [24-26].
Notably, systemic and/or local concentrations of sev-
eral other cytokines, such as IL-6, are also significantly
elevated in pSS patients compared to normal individuals
[27,28]. IL-6 promotes the differentiation of B cells [29],
which play a pivotal role in the production of autoanti-
bodies and hence in the development of pSS. Since
monocytes produce both IL-6 [30] and BAFF [2,4,31],
we hypothesized that the production of these cytokines
is dysregulated in pSS monocytes. If that is the case,
aberrations of pSS monocytes may be implicated in the
abnormal production of autoreactive immunoglobulin G
(IgG) by B cells, which is involved in the pathogenesis
of autoimmune diseases such as pSS [32]. In the present
study, we demonstrate that the regulatory mechanisms
for the production of these cytokines are impaired in
pSS monocytes.
Materials and methods
Patients and controls
Venous blood samples were collected from pSS patients
(n = 13 females ages 32 to 64 years (average age =
50.5)) and normal individuals (n = 12 females ages 26 to
60 years (average age = 43.5)) after receiving their
informed consent. Patients fulfilled the American-Eur-
opean Consensus Group criteria for pSS [33]. At the
time of the collection of blood samples, two patients
(15.4%) were receiving prednisolone at a daily dose < 5
mg. The remaining patients were free of medication.
This study was approved by the ethics committees at
Keio University School of Medicine and Saitama Medi-
cal University.
Stimulation of peripheral monocytes in vitro
Peripheral monocytes were isolated as follows: Whole
blood was mixed with RosetteSep Human Monocyte
Enrichment Cocktail (StemCell Technologies, Vancou-
ver, BC, Canada) and centrifuged over Ficoll-Hypaque
(Beckman Coulter, Fullerton, CA, USA). A monocyte-
enriched fraction was collected and cultured overnight
in RPMI 1640 (American Tissue Culture Collection,
Manassas, VA, USA) supplemented with 10% FCS in a
humidified incubator (7% CO2)a t3 7 ° Cs ot h a tt h e
expression of various stress-induced genes subsided.
The cells were then washed once with the medium to
remove debris. Fluorescence-activated cell sorting
(FACS) analysis of the cells demonstrated that > 96% of
the living cells were CD14-positive.
The monocytes were cultured in the absence or pre-
sence of various concentrations of IFN-g or sBAFF, and
the cumulative production of sBAFF and/or IL-6 was
examined by ELISA. The production was dependent on
the incubation period. The optimal incubation period
was found to be 96 hours. The production of the cyto-
kines increased almost in proportion to the concentra-
tion of stimuli up to 200 ng/ml IFN-g or 2 μg/ml
sBAFF.
Antibodies and recombinant proteins
An anti-BAFF mAb for ELISA was prepared in our
laboratory [6]. A rabbit polyclonal anti-BAFF antibody
and recombinant human sBAFF were purchased from
Chemicon International (Temecula, CA, USA). Recom-
binant human IFN-g,ac o n t r o lm o u s eI g G 1 ,a n dm A b s
for measurement of the amount of IL-6 by ELISA
(MQ2-13A5 and MQ2-39C3 for capture and detection,
respectively) and for FACSa n a l y s i s( C D 4 - A P C( R P A -
T4) for T cells, CD14-PE-Cy7 (M5E2) for monocytes,
CD20-APC-Cy7 (L27) for B cells and CD268-FITC
(11C1) for BAFF-R) were purchased from BD Bios-
ciences/Pharmingen (San Diego, CA, USA). An anti-
TACI antibody for FACS analysis (CD267-PE
(FAB1741P)) was purchased from R&D Systems (Min-
neapolis, MN, USA).
ELISA
Monocytes were cultured at 2.5 × 10
5/ml for 96 hours
in a 24-well plate (2 ml/well) in the presence of stimuli
(that is, recombinant human IFN-g or recombinant
human sBAFF). The amounts of sBAFF (in response to
IFN-g as a stimulus) and IL-6 (in response to IFN-g or
sBAFF as stimuli) in the culture supernatants were mea-
sured by sandwich ELISA according to previously
described methods [6], except for the concentrations of
capture and detection antibodies for IL-6, which were
prepared at 0.5 μg/ml.
For quantitation of sBAFF, we used our own anti-
BAFF mAb, which specifically detects sBAFF and does
not react with a proliferation-inducing ligand (APRIL)
[6]. In our hands, the sensitivity of our ELISA system
was better than that of commercially available ELISA
kits (R&D Systems) in the range of 0.4 to 100 ng/ml
sBAFF (data not shown).
Quantitation of the gene expression levels
The expression levels of BAFF, BAFF-R, TACI, NF-IL6,
NF-IL6b,N F - B1, NF-B2 and glyceraldehyde 3-phos-
phate dehydrogenase (GAPDH) were quantitated by
using a method described previously [6]. The following
oligonucleotides were used as primers for PCR: 5’-
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(BAFF-R); 5’-agcatcctgagtaatgagtggcc and 5’-gagcttgttct-
cacagaagtatgc (TACI); 5’-aaaactttggcactggggcacttg and
5’-catctttaagcgattactcagggc (NF-IL6); 5’-agatgcagca-
gaagttggtggag and 5’-tagcttctctcgcagtttagtgg (NF-IL6b);
5’-atgggatctgcactgtaactgc and 5’-tcatagatggcgtctgataccacg
(NF-B1); 5’-cctgactttgagggactgtatcca and 5’-gcagcatttag-
cagcaaggtcttc (NF-B2). Primer sets for BAFF and
GAPDH were designed as described previously [6]. The
expression level of each gene underwent dual normaliza-
tion against GAPDH expression and expression of the
same gene in unstimulated normal monocytes.
FACS analysis
FACS and data analyses were carried out on a MACS-
Quant Analyzer (Miltenyi Biotec, Bergisch Gladbach,
Germany). FACS analysis of cells in whole blood was
carried out according to methods recommended by the
manufacturer of the antibodies (BD Biosciences/
Pharmingen).
Statistical analysis
Differences between groups were examined for statistical
significance by using the two-tailed Student’s t-test for
single comparisons. Two-way analysis of variance
(ANOVA) was also employed when appropriate. A P
value less than 0.05 denoted the presence of a statisti-
cally significant difference.
Results
Aberrant production of sBAFF by pSS monocytes
Peripheral monocytes were prepared from primary pSS
patients and normal individuals. The clinical characteris-
tics of the pSS patients involved in this study are listed
in Table 1. The cells were cultured for 96 hours in the
absence or presence of IFN-g (200 ng/ml), which is
known to activate monocytes [34] and upregulate the
expression of BAFF [2]. Stimulation of the cells was
confirmed by the induction of interferon-gamma
inducible protein 10 (data not shown). pSS monocytes
released a significantly higher amount of sBAFF (5.4 ±
0.8 ng/ml) into the culture media than normal mono-
cytes did (1.6 ± 0.3 ng/ml), even in the absence of sti-
mulation, suggesting dysregulated production of sBAFF
in pSS monocytes (Figure 1A, “Normal -” and “pSS -”).
IFN-g stimulation (Figure 1A, “Normal +” and “pSS +”)
resulted in an increase in sBAFF in both normal (6.6 ±
1.6 ng/ml) and pSS monocytes (21.1 ± 2.1 ng/ml).
RT-PCR analysis indicated that the expression of the
BAFF gene in pSS monocytes was distinctly elevated
upon stimulation with IFN-g (Figure 1B). Quantitative
RT-PCR analysis indicated that the relative expression
Table 1 Clinical characteristics of primary Sjögren’s
syndrome patients involved in this study
Patient characteristics Clinical data
Female (%) 100
Mean age ± SD (years) 50.5 ± 10.2
Subjective ocular dryness (%) 100
Subjective oral dryness (%) 100
Presence of anti-SSA/Ro (%) 61.5
Presence of anti-SSB/La (%) 23.1
Presence of rheumatoid factor (%) 53.8
Mean serum IgG ± SD (μg/ml) 1,979.6 ± 870.5
Steroid medication (%) 15.4
IgG = immunoglobulin G.
Figure 1 Production of sBAFF by peripheral monocytes.
Monocytes (2.5 × 10
5/ml) were cultured for 96 hours in the
absence (-) or presence (+) of recombinant human IFN-g (200 ng/
ml). (A) The amounts of soluble B-cell-activating factor of the TNF
family (sBAFF) in the culture supernatants of normal individuals
(open circles) and primary Sjögren’s syndrome (pSS) patients (closed
circles) were quantitated in triplicate measurements by sandwich
ELISA. Bars indicate means. **P < 0.01 and ***P < 0.001. (B) Total
RNAs were prepared from normal and pSS monocytes and
subjected to RT-PCR for BAFF and glyceraldehyde 3-phosphate
dehydrogenase (GAPDH). Representative data are shown.
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pSS monocytes than in normal monocytes under unsti-
mulated conditions. The expression levels increased
about sixfold in both normal and pSS monocytes upon
stimulation with IFN-g. These data are basically consis-
tent with the results derived by ELISA. Therefore, we
postulated that the elevated production of sBAFF was
the consequence of the enhanced expression of the
BAFF gene.
Aberrant production of IL-6 by pSS monocytes
We also investigated whether the production of IL-6 by
pSS monocytes was abnormal. As indicated in Figure 2,
pSS monocytes produced significantly higher amounts
of IL-6 than normal monocytes without stimulation
(Figure 2, open column vs checkerboard column; P <
0.01). Stimulation of pSS monocytes with 200 ng/ml
IFN-g induced a striking increase (8.6-fold; P < 0.001) in
IL-6 production (Figure 2, checkerboard column vs
closed column). Since IFN-g induced the expression of
BAFF (Figure 1) and BAFF is able to activate monocytes
[35,36], these results suggest that BAFF produced by
monocytes may act in an autocrine fashion to augment
the expression of IL-6. To test this hypothesis, we sti-
mulated pSS monocytes with IFN-g in the presence of
an anti-BAFF mAb [6]. Interestingly, the mAb sup-
pressed IL-6 production in part, but significantly so (P <
0.05) (Figure 2, closed column vs hatched column,
whereas a control antibody had no effect (Figure 2,
closed column vs gray column). These results suggest
that the signal transduction pathway mediated by BAFF
is implicated in the regulati o no fI L - 6p r o d u c t i o nb y
IFN-g-primed monocytes.
If this is really the case, then exogenously supplemen-
ted sBAFF should affect the production of IL-6 by
monocytes. As expected, recombinant human sBAFF
induced the production of IL-6 by both normal (Figure
3, closed circles) and pSS (Figure 3, open circles) mono-
cytes in a dose-dependent manner. pSS monocytes pro-
duced approximately six times more abundant IL-6 than
normal monocytes in the presence of 2 μg/ml sBAFF
(Figure 3). It should be noted that two-way ANOVA
revealed that disease status (normal or pSS) had signifi-
cantly stronger effects than stimulation with sBAFF (P <
Figure 2 Production of IL-6 by peripheral monocytes
stimulated with IFN-g. Monocytes (2.5 × 10
5/ml) prepared from
normal individuals (Nr) (open column) and primary Sjögren’s
syndrome (pSS) patients (checkerboard column) were cultured for
96 hours without stimulation. pSS monocytes were similarly cultured
in the presence of 200 ng/ml of recombinant human IFN-g (closed,
hatched and gray columns), and simultaneously exposed to none
(closed column), an anti-BAFF antibody (10 μg/ml; hatched column)
or a control IgG (10 μg/ml; gray column). The amounts of IL-6 in
the culture supernatants were measured by sandwich ELISA. BAFF =
B-cell-activating factor of the TNF family; IgG = immunoglobulin G.
Data represent means ± SEM. *P < 0.05 and **P < 0.01.
Figure 3 Production of IL-6 by peripheral monocytes
stimulated with sBAFF. Monocytes (2.5 × 10
5/ml) prepared from
normal individuals (closed circles) and primary Sjögren’s syndrome
(pSS) patients (open circles) were cultured for 96 hours in the
presence of 0, 0.5, 1.0 and 2.0 μg/ml of recombinant human soluble
B-cell-activating factor of the TNF family (sBAFF). The amounts of IL-
6 in the culture supernatants were measured by sandwich ELISA.
Data represent means ± SEM. **P < 0.01.
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production by monocytes.
A 2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetra-
zolium-5-carboxanilide (XTT) assay in a separate experi-
ment indicated that 2 μg/ml sBAFF supported the
survival of both normal and pSS monocytes during the
culture period. However, there was no significant differ-
ence in survival rates between normal and pSS mono-
cytes (data not shown), suggesting that higher
production of IL-6 was not simply a consequence of
enhanced survival of monocytes. These data suggest that
the regulatory mechanism for IL-6 production is aber-
rant in pSS monocytes.
Aberrant expression of BAFF receptors in pSS monocytes
Although it has been reported that BAFF receptors are
mainly expressed in lymphocytes [37], our results sug-
gest that BAFF receptors are also expressed in mono-
cytes. RT-PCR detected mRNA for BAFF-R in
monocytes. Notably, the expression level of BAFF-R was
significantly elevated in pSS monocytes (2.1-fold; P <
0.001) compared to normal monocytes (Table 2). In
accordance with these data, FACS analysis indicated
that approximately 60% of pSS monocytes were BAFF-
R-positive (mean fluorescence intensity (MFI) = 50),
whereas only about 25% of normal monocytes were
positive to the same antibody (MFI = 20) (Figure 4A).
The proportion of TACI-positive monocytes was rela-
tively low compared to BAFF-R-positive cells (Figure
4B). Although the population of TACI-positive mono-
cytes seemed to increase slightly in pSS compared to
control monocytes (Figure 4B), the expression level of
the TACI gene was not significantly increased (Table 2).
FACS analysis of lymphocytes in whole blood indi-
cated that there were no significant differences between
pSS patients and normal individuals in the population of
BAFF-R-positive B and T cells (Figures 4C and 4D). All
these data suggest that the expression of BAFF-R is dys-
regulated in pSS monocytes and that this dysregulation
seems to be specific to monocytes among the cells
examined thus far.
Aberrant expression of transcription factors in pSS
monocytes
In an attempt to elucidate a possible mechanism of
sBAFF-mediated overproduction of IL-6 by pSS mono-
cytes, we investigated the expression levels of transcrip-
tion factors involved in the expression of the IL-6 gene
(that is, NF-IL6 (CCAAT/enhancer-binding protein b),
NF-IL6b (CCAAT/enhancer-binding protein δ), NF-B1
and NF-B2). The relative expression levels of all the
transcription factors were significantly elevated in pSS
monocytes compared with the control (Table 3).
Remarkably, the relative expression level of NF-IL6 was
more than six times higher in pSS monocytes than in
normal monocytes. These data indicate that the expres-
sion of IL-6-regulating transcription factors was abnor-
mally upregulated in pSS monocytes.
Discussion
Several lines of circumstantial evidence have suggested
that BAFF and IL-6 are implicated in the development
of primary pSS [19-23,27,28,38]. In addition, these cyto-
kines are produced by monocytes [2,4,39,40]. These
findings prompted us to investigate the possibility of
aberrations in the monocytes of pSS patients. We
hypothesized that the production of these cytokines is
dysregulated in pSS monocytes. To address this issue,
we examined the production of these cytokines by per-
ipheral pSS monocytes in vitro in response to IFN-g,a
cytokine known to upregulate BAFF expression [2,41].
As expected, pSS monocytes produced a higher amount
of sBAFF than normal monocytes, even in the absence
of stimulation (Figure 1A).
IFN-g also induced the production of IL-6 by pSS
monocytes. Interestingly, the induction was suppressed
in part, but significantly, by an anti-BAFF antibody (Fig-
ure 2). In addition, exogenously supplemented sBAFF
induced a striking increase in the production of IL-6 by
pSS monocytes (Figure 3), whereas exogenously supple-
mented IL-6 had no effects on the production of sBAFF
by the cells (data not shown). These data, together with
the results shown in Figure 1A, collectively imply that
BAFF produced by monocytes act in an autocrine fash-
ion and that signal transduction pathways mediated by
BAFF are likely involved in the regulation of IL-6 pro-
duction by monocytes. Notably, two-way ANOVA indi-
cated that pSS monocytes were more susceptible than
normal monocytes to stimulation by sBAFF. This
increased susceptibility may be due to an exaggeration
of signals in pSS monocytes triggered by sBAFF.
BAFF is known to bind to several receptors, such as
TACI, BAFF-R and BCMA [8,10,11,13]. BAFF binds
TACI [42] and BAFF-R [43,44] with high affinity,
whereas the binding affinity of BAFF to BCMA is very
low [44,45]. We found that a relatively small population
Table 2 Expression of BAFF receptors in peripheral
monocytes
Receptor Normal pSS
TACI 100.0 ± 17.6 121.7 ± 20.4
BAFF-R 100.0 ± 5.9 213.8 ± 14.9***
BAFF = B-cell-activating factor of the TNF family; pSS = primary Sjögren’s
syndrome; TACI = transmembrane activator and calcium-modulator and
cyclophilin ligand interactor. Monocytes (2.5 × 10
5/ml) prepared from normal
individuals ("Normal”) and pSS patients ("pSS”) were cultured for 96 hours
without stimulation. Total RNAs were extracted from the cells, and the
expression levels of TACI and BAFF-R were quantitated. The relative
expression levels of the genes are indicated. Data represent means ± SEM.
Asterisk denotes statistically significant difference between “Normal” and
“pSS.” ***P < 0.001.
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that the expression level of TACI did not increase in
pSS patients (Table 2). Interestingly, expression of
BAFF-R, a BAFF-specific receptor, was significantly ele-
vated in pSS monocytes compared to the control (Table
2). FACS analysis suggested that this elevation may be
the consequence of an increase not only in the popula-
tion of BAFF-R-positive cells but also in the expression
of the BAFF-R gene in individual pSS monocytes (Figure
4A). Considering all of this information together, we
believe that abnormally overexpressed BAFF-R may have
contributed to the enhanced production of IL-6 by pSS
monocytes upon stimulation with sBAFF (Figure 3). The
increase in the population of BAFF-R-positive cells was
specific to pSS monocytes among the cells examined
thus far, and no significant differences were observed in
the population of BAFF-R-positive lymphocytes between
pSS and the normal control (Figures 4C and 4D).
To shed light on the aberrant production of IL-6 by pSS
monocytes, we examined the expression levels of several
transcription factors involved in the expression of IL-6.
Interestingly, the expression levels of all the transcription
factors examined in the present study were significantly
elevated compared to normal monocytes (Table 3). The
Figure 4 Fluorescence-activated cell sorting analysis of monocytes and lymphocytes. (A) and (B) Normal (gray line) and primary Sjögren’s
syndrome (pSS) (black line) monocytes were cultured for 96 hours without stimulation, and CD14
+/BAFF-R
+ cells (A) and CD14
+/TACI
+ cells (B)
were examined by fluorescence-activated cell sorting (FACS) analysis. (C) and (D) Lymphocytes in whole blood samples of a normal individual
(gray line) and a pSS patient (black line) were examined by FACS analysis for CD20
+/BAFF-R
+ cells (B cells in part (C)) and CD4
+/BAFF-R
+ cells (T
cells in part (D)). Light gray lines represent isotype controls. Representative data derived by FACS analysis are shown. BAFF-R = B cell activating
factor receptor; TACI = transmembrane activator and calcium modulator and cyclophilin ligand interactor.
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constitutive and insensitive to stimulation, in particular
with regard to sBAFF (data not shown). The expression
level of NF-IL6 was especially high among the transcrip-
tion factors examined. The higher expression of these fac-
tors may have amplified a signal triggered by sBAFF which
resulted in overproduction of IL-6 by pSS monocytes. On
the basis of the results shown in Figure 2 andTable 3 we
suppose that IFN-g induces the production of IL-6 in pSS
monocytes through at least two distinct pathways: one is
direct activation of the IL-6 gene and the other is indirect
activation of the gene mediated by sBAFF.
The relationship between the aberration of pSS mono-
cytes and the clinical manifestations of the disease
remains unclear. There was no significant correlation
between the presence of rheumatoid factor, anti-SSA/Ro
or anti-SSB/La in pSS patients and the amounts of IL-6
and sBAFF produced by pSS monocytes. However, den-
dritic cells have been observed in the salivary glands of
pSS patients [46-48], and peripheral monocytes can
migrate to the salivary glands and develop into dendritic
cells [49-51]. In addition, the local concentration of
IFN-g in the salivary glands of pSS patients seems to be
increased because of T cells’ infiltrating the tissue
[51,52]. Therefore, we hypothesize that monocyte-
derived dendritic cells infiltrating the salivary glands of
pSS patients are stimulated by IFN-g to produce exces-
sive amounts of BAFF and IL-6.
Conclusions
Although the number of the patients involved in the
current study was small, the data strongly suggest that
monocytes of pSS patients are abnormally activated. We
hypothesize that stimulation of pSS monocytes by IFN-g
is partly mediated by BAFF as a result of the abnormal
overexpression of BAFF-R and that the signals are
amplified by abnormal overexpression of transcription
factors that regulate IL-6 production. We speculate that
these aberrations may underlie the pathogenesis of pSS.
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